The Discrepancy Between Genetic Polymorphism of p53 Codon 72 and the Expression of p53 Protein in Helicobacter pylori-Associated Gastric Cancer in Korea
- 178 Downloads
The p53 gene has been referred to as ‘the guardian of the genome’ because it controls apoptosis and cell cycle arrest. The purpose of this study was to evaluate the association of p53 codon 72 genetic polymorphism and the p53 immunohistochemistry with Helicobacter pylori-associated gastroduodenal diseases, including gastric cancer. This study included 1,852 subjects: controls and patients with gastric cancer, dysplasia, benign gastric ulcers, and duodenal ulcers (DU). Biallelic polymorphism was genotyped by restriction fragment length polymorphism. Immunohistochemical analysis for the detection of mutant type p53 expression was performed. The frequency of the Pro/Pro allele of the p53 codon 72 was higher in the patients with H. pylori-positive dysplasia than in controls (OR: 2.3, 95% CI: 1.3–4.3), but it was less frequent among patients with a H. pylori-positive DU (OR: 0.5, 95% CI: 0.3–0.8). However, there was no significant association with gastric cancer, including the location, stage, or histological type of gastric cancer. Expression of a mutant type of p53 protein was detected in 6.3% of dysplastic tissues and 26.5% of cancerous tissues compared 0% in the controls. Positive expression was higher in the intestinal type of cancer (34.9%) than in the diffuse type (15.0%; P = 0.001). These results suggest that genetic polymorphism of p53 codon 72 played a role in the determination of H. pylori-associated gastroduodenal diseases, but p53 immunostaining did not correlate with those of the p53 genetic polymorphism analysis.
Keywordsp53 Helicobacter pylori Gastric cancer Genetic polymorphism
This work was supported by a grant from the Korean Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (no. A060266).
- 40.Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus: immunohistological marker predictive of progression. Am J Gastroenterol. 2001;96:1355–1362. doi: 10.1111/j.1572-0241.2001.03851.x.CrossRefPubMedGoogle Scholar
- 42.Dixon MF, Genta RM, Yardley JH, Correa P. The participants on the International workshop on the Histopathology of Gastritis, Houston 1994. Classification and grading of gastritis: the Updated Sydney System. Am J Surg Pathol. 1996;20:1161–1181. doi: 10.1097/00000478-199610000-00001.CrossRefPubMedGoogle Scholar
- 55.Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma—a molecular and immunochemical study with clinicopathologic correlations. Cancer. 1997;79:425–432. doi:10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO;2-H.CrossRefPubMedGoogle Scholar
- 58.Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systemic review. Br J Cancer. 2005;92:434–444.Google Scholar